Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis;Ustekinumab en paciente con enfermedad de Crohn y psoriasis inducida por anti-TNF-α

Gastroenterologia y Hepatologia

Volumn 34, Issue 8, 2011, Pages 546-550

  Sansó Sureda, Andrés ^a   Rocamora Durán, Vicenç ^a   Sapiña Camaró, Amparo ^a   Royo Escosa, Vanesa ^a   Bosque López, María José ^a  

^a HOSPITAL DE MANACOR   (Spain)

Author keywords

Anti TNF ; Crohn's disease; Psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; INFLIXIMAB; USTEKINUMAB;

ARTICLE; CASE REPORT; CROHN DISEASE; FEMALE; HUMAN; PSORIASIS; TREATMENT WITHDRAWAL;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12 SUBUNIT P40; MESALAMINE; PHOTOTHERAPY; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053935432     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.04.003     Document Type: Article

References (25)

1. Hanauer S.B., Sandborn W. The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001, 96:635-643.
2. Travis S.P., Stange E.F., Lemann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006, 55(Suppl 1):i16-35.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients withCrohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
5. Schreiber S., Khaliq-Kareemi M., Lawrance I., Thomsen O., Hanauer S.B., McColm J., et al. Certolizumab pegol maintenance therapy for Crohn's disease. N Engl J Med 2007, 357:239-250.
6. Peyrin-Biroulet L., Deltenre P., De Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
7. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
8. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009, 20:100-108.
9. Peluso I., Pallone F., Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006, 12:5606-5610.
10. Neurath M.F. IL-23: a master regulator in Crohn disease. Nat Med 2007, 13:26-28.
11. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
12. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patiens with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
13. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
14. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
15. Rahier J.F., Buche S., Biroulet L.P., Bouhnik Y., Duclos B., Louis E., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8:1048-1055.
16. Fiorino G., Allez M., Malesci A., Danese S. Anti TNF-α induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:921-927.
17. Palucka A.K., Blanck J.P., Bennett L., Pascual V., Banchereau J. Cross-regulation of TNF and IFN- α in autoimmune diseases. Proc Natl Acad Sci USA 2005, 102:3372-3377.
18. De Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
19. Nestle F.O., Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for Interferon- α. J Invest Dermatol 2005, 125:14-16.
20. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 17:244-279.
21. Michaëlsson G., Kajermo U., Michaëlsson A., Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-a in the normal palmar eccrine sweat duct?. Br J Dermatol 2005, 153:1243-1244.
22. Teraki Y., TanaKa S., Hitomi K., Izaki S. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis. Br J Dermatol 2010, 163:1347-1351.
23. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40:233-240.
24. Wollina U., Hansel G., Koch A., Schönlebe J., Köstler E., Haroske G. Tumor necrosis factor-alpha inhibitor- induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
25. Aslanidis S., Pyrpasopoulou A., Douma S. Tumor necrosis factor- α antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol 2008, 27:377-380.